TD Cowen raises Avita Medical stock price target on growth outlook
TD Cowen raised its price target for Avita Medical (RCEL) to $22.00 from $20.00, citing 20-25% annual revenue growth and stable operating expenses through 2027. The stock trades at $17.35, near its 52-week high. Avita reported Q3 2026 earnings beating estimates, with revenue up 53% year-over-year.
How this was made
The 30-second read
Why it matters
The analyst's upgrade and target increase provide a fresh catalyst that could attract new buying, especially given the company's high gross margin and upcoming cash‑flow generation timeline.
Market read
Micro‑cap biotech with a new analyst target may see short‑term price appreciation.
What to watch
Potential regulatory or reimbursement hurdles for RECELL could temper growth.
Background
Avita Medical (RCEL) reported Q3 2026 earnings that beat expectations, prompting TD Cowen to lift its price target.
Ticker impact
TD Cowen raised its price target on Avita Medical to $22 from $20 and highlighted Q3 earnings beat and growth outlook.
likely upward pressure as investors price in the new $22 target.
Target raise of 10% with fresh earnings beat provides a clear catalyst for buying interest.
Market effects
Positive outlook for regenerative medicine and wound‑care sector may lift peers.
Limited to US biotech investors; no broader regional effect.
Minor, confined to niche biotech space.
Counterpoint
Target raise may be premature if cash generation delays beyond 2027.
Key entities
- AnalystTD Cowen
Equity research firm that raised the price target.
- CompanyAvita Medical Ltd.
Biotech firm developing RECELL and Cohealyx products.


